** Shares of Divi's Laboratories Ltd DIVI.NS up 4.8% at
5,811.70 rupees
** DIVI rose as much as 6% to record 5,878 rupees earlier in
session
** Citi begins coverage of drugmaker with "buy" and
Street-high PT of 6,400 rupees as it sees DIVI benefiting from
supply-chain diversification of active pharmaceutical
ingredients for GLP-1s or weight loss drugs
** DIVI has potential to become prominent supplier to Eli
Lilly LLY.N as it diversifies suppliers with U.S. Biosecure
Act looming and given DIVI's own capabilities in scaling up at
industrial scale - Citi
** Analysts tracking DIVI rate it "hold" on avg, same as 10
other stocks on 20-member Nifty Pharma .NIPHARM index - LSEG
data
** DIVI top pct gainer on NIPHARM
** Stock's ~48% YTD rise outperforms index's 40% rise
(Reporting by Nandan Mandayam in Bengaluru)
((Nandan.Mandayam@thomsonreuters.com; Mobile: +91 9591011727;))